Initiator Pharma reports positive results from the 28 days toxicology study in mini-pigs for its lead drug candidate IPED2015
PRESS RELEASE 15th December, 2017 Initiator Pharma, a biotech company developing a novel treatment of Erectile Dysfunction (ED), has successfully completed an in vivo 28 days toxicology study in mini-pigs for its drug candidate IPED2015, thus moving the development program forward towards the Clinical Trial Application (CTA) and with the aim of initiating a Phase 1 clinical trial next year.During 2017 Initiator Pharma has initiated and completed several toxicology and toxicokinetic studies as well safety pharmacology and genotoxicity studies for its lead drug candidate IPED2015. The